{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T12:51:10Z","timestamp":1764852670327,"version":"3.46.0"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:00:00Z","timestamp":1759363200000},"content-version":"vor","delay-in-days":274,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research Reports"],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/j.lrr.2025.100548","type":"journal-article","created":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T03:42:07Z","timestamp":1759549327000},"page":"100548","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Pediatric-inspired (R3) vs. Adult salvage (FA) chemotherapy in relapsed adolescents and young adults (AYA) acute lymphoblastic leukemia (ALL): A comparative outcome analysis"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8978-7994","authenticated-orcid":false,"given":"Chokri Ben","family":"Lamine","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed","family":"Alshehri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lara","family":"Samhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maha Abdullah","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tusneem Ahmed M.","family":"Elhassan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riad","family":"Elfakih","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feras Abdulaziz","family":"Alfraih","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syed Osman","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amr","family":"Hanbali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"21","key":"10.1016\/j.lrr.2025.100548_bib0001","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1182\/blood.V124.21.796.796","article-title":"Favorable outcomes for older adolescents and young adults (AYA) with acute lymphoblastic leukemia (ALL): early results of US Intergroup Trial C10403","volume":"124","author":"Stock","year":"2014","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.lrr.2025.100548_bib0002","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1080\/14737140.2022.2093718","article-title":"The current treatment approach to adolescents and young adults with acute lymphoblastic leukemia (AYA-ALL): challenges and considerations","volume":"22","author":"Jain","year":"2022","journal-title":"Expert Rev. Anticancer Ther."},{"issue":"21","key":"10.1016\/j.lrr.2025.100548_bib0003","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1182\/blood.V118.21.1524.1524","article-title":"Outcomes for Adult Lymphoblastic Leukemia (ALL) Are mainly influenced by age and status of minimal residual disease (MRD) by multiparameter flow cytometry (MFC) after therapy with the modified hyper-CVAD (with or without rituximab) regimen","volume":"118","author":"Thomas","year":"2011","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.lrr.2025.100548_bib0004","doi-asserted-by":"crossref","first-page":"3572","DOI":"10.1182\/blood.V120.21.3572.3572","article-title":"Outcomes continue to be favorable for de novo Philadelphia chromosome negative B-lymphoblastic leukemia (ALL) after therapy with hyper-CVAD (with or without rituximab) regimen","volume":"120","author":"Thomas","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.lrr.2025.100548_bib0005","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.642466","article-title":"PD-1 inhibition enhances blinatumomab response in a UCB\/PDX model of relapsed pediatric B-cell acute lymphoblastic leukemia","volume":"11","author":"Wunderlich","year":"2021","journal-title":"Front. Oncol."},{"issue":"3","key":"10.1016\/j.lrr.2025.100548_bib0006","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s12185-022-03323-x","article-title":"Feasibility of ovarian stimulation for fertility preservation during and after blinatumomab treatment for Ph-negative B-cell acute lymphoblastic leukemia","volume":"116","author":"Tashiro","year":"2022","journal-title":"Int.l J.Hemat."},{"key":"10.1016\/j.lrr.2025.100548_bib0007","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1171568","article-title":"Management of B-cell lineage acute lymphoblastic leukemia: expert opinion from an Indian panel via Delphi consensus method","volume":"13","author":"Mathews","year":"2023","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.lrr.2025.100548_bib0008","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.1365-2141.2005.05572.x","article-title":"Outcome after first relapse in childhood acute lymphoblastic leukaemia\u2013lessons from the United Kingdom R2 trial","volume":"130","author":"Roy","year":"2005","journal-title":"British J. Haematol."},{"issue":"11","key":"10.1016\/j.lrr.2025.100548_bib0009","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1002\/pbc.26129","article-title":"Treatment-related adverse events associated with a modified UK ALLR3 induction chemotherapy backbone for childhood relapsed\/refractory acute lymphoblastic leukemia","volume":"63","author":"Sun","year":"2016","journal-title":"Pediatric Blood Cancer"},{"issue":"3","key":"10.1016\/j.lrr.2025.100548_bib0010","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/bjh.14569","article-title":"A phase 1 trial of temsirolimus and intensive re-induction chemotherapy for 2nd or greater relapse of acute lymphoblastic leukaemia: a Children's Oncology Group study (ADVL 1114)","volume":"177","author":"Rheingold","year":"2017","journal-title":"Brit. J. Haematol."},{"issue":"3","key":"10.1016\/j.lrr.2025.100548_bib0011","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/MPH.0000000000000318","article-title":"Adolescent and young adult (AYA) oncology in the United States: a specialty in its late adolescence","volume":"37","author":"Shaw","year":"2015","journal-title":"J. Pediatric Hematol.\/Oncol."},{"issue":"4","key":"10.1016\/j.lrr.2025.100548_bib0012","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/bjh.15208","article-title":"Relapse in teenage and young adult patients treated on a paediatric minimal residual disease stratified ALL treatment protocol is associated with a poor outcome: results from UKALL2003","volume":"181","author":"Sellar","year":"2018","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.lrr.2025.100548_bib0013","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1001\/jamaoncol.2017.5305","article-title":"Pediatric-inspired treatment regimens for adolescents and young adults with Philadelphia chromosome\u2013negative acute lymphoblastic leukemia: a review","volume":"4","author":"Siegel","year":"2018","journal-title":"JAMA Oncol."},{"issue":"3","key":"10.1016\/j.lrr.2025.100548_bib0014","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/s41375-021-01460-6","article-title":"Outcomes in adolescent and young adult patients (16 to 30 years) compared to younger patients treated for high-risk B-lymphoblastic leukemia: Report from Children\u2019s Oncology Group Study AALL0232","volume":"36","author":"Burke","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.lrr.2025.100548_bib0015","article-title":"The interplay of financial toxicity, health care team communication, and psychosocial well-being among rural cancer patients and survivors","author":"Miller","year":"2023","journal-title":"J. Rural Health"}],"container-title":["Leukemia Research Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213048925000500?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213048925000500?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T12:47:02Z","timestamp":1764852422000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213048925000500"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":15,"alternative-id":["S2213048925000500"],"URL":"https:\/\/doi.org\/10.1016\/j.lrr.2025.100548","relation":{},"ISSN":["2213-0489"],"issn-type":[{"type":"print","value":"2213-0489"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pediatric-inspired (R3) vs. Adult salvage (FA) chemotherapy in relapsed adolescents and young adults (AYA) acute lymphoblastic leukemia (ALL): A comparative outcome analysis","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lrr.2025.100548","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100548"}}